The first rapid tests to detect COVID-19 in the south of Russia began to be produced in the Crimea

The first production of rapid tests in the south of Russia to detect infectious diseases, including COVID-19, has been opened in the Republic of Crimea. The Deputy Chairman of the Council of Ministers - Minister of Finance of the Republic of Crimea Irina Kiviko reported, opening a production site for the assembly of express tests in Simferopol.

"The Republic of Crimea has become the first in the south of Russia to master the production of rapid tests. We have fulfilled the instruction of the President of the Russian Federation on the prevention of a new coronavirus infection. Now the volume of testing to detect COVID-19 will be significantly increased," Irina Kiviko said.

The opening of production was attended by: the Deputy Chairman of the Council of Ministers - Minister of Finance of the Republic of Crimea Irina Kiviko, Minister of Economic Development of the Republic of Crimea Dmitry Sheryako, heads of ministries and departments, representatives of "White Product" and "KrymTest", the Crimea Development Corporation.

The agreement of intent on the release of rapid tests was signed on October 21, 2021 between the Council of Ministers of the Republic and the Russian company "White Product", which is one of the leaders of the express diagnostics market in Russia.

Production is deployed in Simferopol on the basis of the company "KrymTest". The Crimea Development Corporation supports the investment project.
The general director of the company "Krymtest" Elena Sharova said that the assembly of rapid tests will take place in compliance with the necessary sanitary requirements, including the sterility of production. Now a pilot batch of products for registration with Roszdravnadzor will be developed here.

According to her, the creation of a comprehensive localized production site under the brand name "KrymTest" will allow the production of a wide range of 68 names of test systems for the detection of infectious diseases in humans. These are respiratory, such as COVID-19, influenza A/B, RSV, adenovirus, streptococcus A, mycoplasma, intestinal infections: rotavirus, H.pylori, typhoid fever, oncological diseases, HIV and others.

The planned capacity is up to 100 thousand rapid tests per month. The rapid tests produced consist of premium components and allow us to identify existing strains of coronavirus, including the new "omicron".

The "White Product" company, even at the beginning of the spread of coronavirus infection, offered the Russian market systems for rapid diagnosis of coronavirus infection from a world manufacturer from South Korea, which has become a leader in laboratory research and diagnostics of COVID-19 and other infectious diseases.

The "White Product" is one of the key suppliers of the Russian market of test systems for the detection of coronavirus infection. The rapid tests supplied by the company to the Russian market have the highest accuracy indicators – a sensitivity index to the virus antigen of 96%. The use of the test system does not require additional laboratory equipment and is available for use outside medical and preventive institutions.

The test systems are designed for qualitative detection of the coronavirus antigen (SARS-CoV-2) in human nasopharyngeal smear samples from the first day of the appearance of clinical symptoms. The test result can be obtained in 15-30 minutes. Tests are able to determine the presence of the virus antigen as accurately as possible at the lowest concentrations of the virus in the body at the earliest stages of the disease.